The biological underpinnings of therapeutic resistance in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively adapt to and resist therapeutic intervention. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Beatty, Gregory L., Werba, Gregor, Lyssiotis, Costas A., Simeone, Diane M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247606/
https://www.ncbi.nlm.nih.gov/pubmed/34117095
http://dx.doi.org/10.1101/gad.348523.121
Descripción
Sumario:Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively adapt to and resist therapeutic intervention. In this review, we discuss recent advances in our understanding of the biological underpinnings of PDAC and their implications as targetable vulnerabilities in this highly lethal disease.

Ejemplares similares